Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Korean scientists patent novel DPP IV inhibitors

Nov. 2, 2012

Semaphorin-3A demonstrates osteoprotective qualities and therapeutic potential

Oct. 31, 2012

Oral salmon calcitonin shows potential as antidiabetic therapy in vivo

Oct. 31, 2012

Takeda submits Japanese NDA for cetilistat

Oct. 31, 2012

E.U. approval for linagliptin as add-on therapy in type 2 diabetes

Oct. 30, 2012

ViaCyte receives grant to continue development of diabetes therapy

Oct. 30, 2012

FDA turns down request for appeal on NDA for vaginal gel in preterm birth

Oct. 29, 2012

New GPR119 receptor agonists disclosed by Arena Pharmaceuticals

Oct. 29, 2012

Chugai enters Japanese license agreement for CSG-452

Oct. 29, 2012

FDA accepts NDA filing for controlled-release misoprostol vaginal insert

Oct. 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...